HIGHER RISK GROUPS

Consensus-based recommendation for higher risk groups

This page is part of the PanCare follow-up recommendations for surveillance of late effects. Click here, for more information on these recommendations.

Click here, to read this recommendation in PLAIN language.

Higher risk groups

Some high-risk survivors, for example some CNS tumour survivors, have a greater risk of being affected in different areas simultaneously, such as in their physical health, mental health, social skills, activities of daily living, school or work. A comprehensive approach should be used to identify and address these problems.

In addition, survivors treated with allogeneic HSCT and their HCPs should be aware of the risk of chronic GvHD, which may affect any organ system, especially the skin, mouth, eyes, liver, lungs, gastro-intestinal tract, joints and muscles.

It should be noted that greater caution for late effects is warranted in those survivors who have suffered significant acute toxicity during treatment.

Sometimes, supportive treatment may contribute to long-term adverse effects (for example, increased risk of non-melanoma skin cancer after prolonged voriconazole treatment, or renal toxicity after aminoglycoside use).

Survivors with, or with a suspicion of, a hereditary cancer syndrome should receive additional consultation by a clinical geneticist to determine individualised surveillance methods and frequency based on current available knowledge.